Skip to main
ACON
ACON logo

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc has demonstrated significant commercial momentum through the establishment of multiple agreements with prominent healthcare institutions, including the Spine Institute of Louisiana and Scripps Health in San Diego. The company reported an impressive 132% year-over-year growth in scans during Q2, coupled with a 76% increase in revenues, signaling a potential for continued upward growth as momentum builds. With the accelerating uptake of its Nociscan SaaS platform, Aclarion positions itself favorably within the healthcare technology sector, enhancing its prospects for future revenue generation.

Bears say

Aclarion Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from slower-than-anticipated traction with insurance payers, which could negatively impact revenue growth. Additionally, the company has adjusted its FY25 earnings per share estimate to $(15.08), reflecting an increase in marketing and administrative expenses that undermine overall financial performance. Also critical are potential risks related to liquidity, regulatory approvals, commercialization capabilities, and competition, which collectively present substantial uncertainties for the company's operational viability.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.